Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Share-based Compensation (2018 - 2025)

Autolus Therapeutics (AUTL) has disclosed Share-based Compensation for 5 consecutive years, with $3.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Share-based Compensation fell 4.6% year-over-year to $3.8 million, compared with a TTM value of $17.2 million through Sep 2025, up 37.67%, and an annual FY2024 reading of $15.5 million, up 38.09% over the prior year.
  • Share-based Compensation was $3.8 million for Q3 2025 at Autolus Therapeutics, down from $4.3 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $6.2 million in Q4 2024 and bottomed at -$8.6 million in Q4 2022.
  • Average Share-based Compensation over 4 years is $2.4 million, with a median of $2.9 million recorded in 2024.
  • The sharpest move saw Share-based Compensation skyrocketed 138.09% in 2023, then decreased 5.15% in 2024.
  • Year by year, Share-based Compensation stood at -$8.6 million in 2022, then surged by 138.09% to $3.3 million in 2023, then surged by 90.32% to $6.2 million in 2024, then plummeted by 38.47% to $3.8 million in 2025.
  • Business Quant data shows Share-based Compensation for AUTL at $3.8 million in Q3 2025, $4.3 million in Q2 2025, and $2.9 million in Q1 2025.